NZ726108A - Substituted dihydroisoquinolinone compounds - Google Patents
Substituted dihydroisoquinolinone compoundsInfo
- Publication number
- NZ726108A NZ726108A NZ726108A NZ72610815A NZ726108A NZ 726108 A NZ726108 A NZ 726108A NZ 726108 A NZ726108 A NZ 726108A NZ 72610815 A NZ72610815 A NZ 72610815A NZ 726108 A NZ726108 A NZ 726108A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- salts
- substituted
- substituted dihydroisoquinolinone
- dihydroisoquinolinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013410P | 2014-06-17 | 2014-06-17 | |
US201562156533P | 2015-05-04 | 2015-05-04 | |
PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ726108A true NZ726108A (en) | 2020-06-26 |
Family
ID=53434412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ726108A NZ726108A (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Country Status (40)
Country | Link |
---|---|
US (4) | US9481666B2 (me) |
EP (2) | EP3521285A1 (me) |
JP (1) | JP6152495B1 (me) |
KR (1) | KR101877187B1 (me) |
CN (1) | CN107207464B (me) |
AP (1) | AP2016009605A0 (me) |
AU (1) | AU2015275826B2 (me) |
BR (1) | BR112016029612B1 (me) |
CA (1) | CA2894298C (me) |
CL (1) | CL2016003246A1 (me) |
CR (2) | CR20200484A (me) |
CU (1) | CU24408B1 (me) |
CY (1) | CY1121706T1 (me) |
DK (1) | DK3157915T3 (me) |
EA (1) | EA031892B1 (me) |
ES (1) | ES2721031T3 (me) |
GE (1) | GEP20186933B (me) |
HR (1) | HRP20190604T1 (me) |
HU (1) | HUE042964T2 (me) |
IL (1) | IL248991B (me) |
LT (1) | LT3157915T (me) |
MA (1) | MA40225B1 (me) |
MD (1) | MD4820C1 (me) |
ME (1) | ME03419B (me) |
MX (1) | MX2016016764A (me) |
MY (1) | MY185765A (me) |
NZ (1) | NZ726108A (me) |
PE (1) | PE20161552A1 (me) |
PH (1) | PH12016502378A1 (me) |
PL (1) | PL3157915T3 (me) |
PT (1) | PT3157915T (me) |
RS (1) | RS58632B1 (me) |
SG (1) | SG11201609386YA (me) |
SI (1) | SI3157915T1 (me) |
SV (1) | SV2016005333A (me) |
TN (1) | TN2016000529A1 (me) |
TW (1) | TWI561516B (me) |
UA (1) | UA118380C2 (me) |
UY (1) | UY36170A (me) |
WO (1) | WO2015193765A1 (me) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
TN2016000529A1 (en) | 2014-06-17 | 2018-04-04 | Pfizer | Substituted dihydroisoquinolinone compounds |
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
WO2019016112A1 (en) | 2017-07-17 | 2019-01-24 | AbbVie Deutschland GmbH & Co. KG | SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P |
RU2754131C1 (ru) * | 2017-11-14 | 2021-08-27 | Пфайзер Инк. | Комбинированная терапия ингибитором ezh2 |
AU2019214861B2 (en) | 2018-01-31 | 2021-11-18 | Mirati Therapeutics, Inc. | PRC2 inhibitors |
LT3781561T (lt) | 2018-04-18 | 2024-07-10 | Constellation Pharmaceuticals, Inc. | Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas |
EP3797108B1 (en) * | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
EP3870173A4 (en) * | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 MODULATORS AND INHIBITORS |
EP3929199A4 (en) * | 2019-02-19 | 2022-10-26 | Hanmi Pharmaceutical Co., Ltd. | NEW HETEROCYCLIC COMPOUND AND USE THEREOF |
WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
CA3165787C (en) * | 2020-08-13 | 2023-06-06 | Seung Hyun Jung | Novel dioxoloisoquinolinone derivatives and use thereof |
WO2022122037A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海奕拓医药科技有限责任公司 | 一种二氢异喹啉酮衍生物及其应用 |
CN118302427A (zh) * | 2021-12-02 | 2024-07-05 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
CA2631777A1 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
JP5551689B2 (ja) * | 2008-06-17 | 2014-07-16 | アストラゼネカ アクチボラグ | ピリジン化合物 |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
JP5864545B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インドール |
EP2614369B1 (en) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Method for determining the suitability of inhibitors of human ezh2 in treatment |
JP2013537210A (ja) * | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤 |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
WO2013049770A2 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
EP2900653A1 (en) | 2012-09-28 | 2015-08-05 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
KR20150096684A (ko) | 2012-12-21 | 2015-08-25 | 사노피 | 엑센딘-4 유도체 |
BR122015029881B1 (pt) | 2012-12-21 | 2022-04-26 | Gilead Sciences, Inc | Compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico |
HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
SI2935303T1 (sl) | 2012-12-21 | 2021-08-31 | Janssen Biopharma, Inc. | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV |
MX358684B (es) | 2012-12-21 | 2018-08-31 | Hoffmann La Roche | Peptidos como agonistas de oxitocina. |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
RU2666146C2 (ru) | 2012-12-21 | 2018-09-06 | Плексксикон Инк. | Соединения и способы модулирования киназы и показания к их применению |
FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
TN2016000529A1 (en) | 2014-06-17 | 2018-04-04 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2015
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/me unknown
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active IP Right Grant
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en active Application Filing
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-03-28 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
TN2015000281A1 (fr) | Lactames condenses aryliques et heteroaryliques | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
TW201613864A (en) | Novel compounds | |
PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
NZ727188A (en) | Aldosterone synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2022 BY THOMSON REUTERS Effective date: 20210505 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2023 BY THOMSON REUTERS Effective date: 20220502 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2024 BY THOMSON REUTERS Effective date: 20230501 |